<DOC>
	<DOCNO>NCT00611845</DOCNO>
	<brief_summary>This special access protocol allow physician access aprotinin temporary marketing suspension . The program provide aprotinin treatment surgical patient undergo coronary artery bypass graft ( CABG ) surgery require cardiopulmonary bypass ( CPB ) increase risk bleeding transfusion , opinion treat physician , patient require , acceptable alternative therapy , clearly favorable benefit-risk drug individual patient .</brief_summary>
	<brief_title>Aprotinin US Special Access Protocol</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Aprotinin</mesh_term>
	<criteria>Patients 18 year age old Patients undergo cardiopulmonary bypass course coronary artery bypass graft surgery increase risk blood loss blood transfusion . These patient may include follow : Patients receive preoperative antithrombotic drug ( e.g. , clopidogrel , aspirin ) , Patients undergoing repeat CABG complex CABG procedure , Patients undergoing urgent emergent CABG procedure , Patients refuse receive allogeneic blood product religious reason , Patients undergo primary CABG advance age multiple comorbidities preoperative anemia , coagulopathies , diabetes mellitus , peripheral vascular disease The physician determine acceptable alternative comparable therapy available patient clearly favorable benefitrisk drug individual patient Documented , sign , date informed consent obtain prior entry study Patients know suspect previous aprotinin exposure last 12 month . Aprotinin may also component fibrin sealant product , use product consider evaluate previous aprotinin exposure Patients know suspect allergy aprotinin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>CABG surgery require CPB increase risk bleed blood transfusion</keyword>
</DOC>